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 Abstract 
Introduction: In the last fifteen years a new cause of chronic manganese toxicity has been 
recognized. It follows recreational  intravenous injections of Ephedrone, synthesized from a cold 
remedies contained pseudoephedrine. Potassium permanganate is used as an oxidant. It presents 
with severe parkinsonism-dystonia and a characteristic dysarthria.  
Objectives. We performed a focus perceptual study of dysarthria in Ephedrone  induced  
parkinsonism and compared the findings with the speech disorders seen in Parkinson's disease 
(PD) and Progressive Supranuclear Palsy (PSP).  
Methods. A digital voice recording, perceptual speech analysis (Darley, 1975), serial 
neurological  assessment  and Brain Magnetic Resonance (MR) imaging were performed at the 
Lviv regional Clinical Hospital. The results were analysed at the Institute of Neurology in 
London. 
Results. Dysarthria developed after  8.5±3.2 months of  daily intravenous Ephedrone abuse and 
was an initial symptom  in a third  of cases. It was characterised by a robotic-flat prosody, 
whispering or continuous phonation, an inability to  regulate pitch and volume, frozen lip 
articulation, a variable degree of dystonic tightness, difficulties in speech initiation and  palladia,   
There was no nasality and   swallowing was normal. In some patients speech deteriorated even 
after the discontinuation of Ephedrone. 
 MR imaging, performed soon after drug cessation showed T1 signal hyperintesity in striatum 
and pallidum, especially in the Globus Pallidum interna.   
 3 
 
Conclusion. Ephedrone induced chronic  manganese toxicity can lead to a mixed hypokinetic-
dystonic dysarthria with a distinct dystonic pattern. Perceptual speech analysis can be a helpful 
ancillary investigation in the  differential diagnosis of parkinsonism, and may permit the 
recognition of chronic manganese toxicity.  
Key words: Parkinsonism; Dysarthria, manganism; Globus Pallidum 
 
Introduction 
Chronic manganese (Mn) poisoning is a recognised cause of basal ganglia toxicity[1-2]. A severe 
irreversible parkinsonism with dystonia was first reported by J. Couper (1837) in miners 
following inhalation of dioxide manganese in ore dust [3].  The characteristic  clinical features 
include hypomimia, risus sardonicus  incontinent laughter, early retropulsion with falls 
backwards and a dystonic cock gait [4]. Whispering dysarthria and mutism have been recorded 
[5]. As the fourth most widely used metal, manganese poisoning continues to be a common 
occupational hazard [6-7].T1 MR hyperintensities in the basal ganglia, typical of manganese 
accumulation, help the diagnosis, but may disappear after exposure has ceased [8,9].  Chronic 
liver disease is another cause of accumulation of manganese in the basal ganglia. Cirrhosis 
induced parkinsonism is reported in 1% patients with liver failure [10]. Parkinsonism with  
dystonia, polycythaemia  and liver cirrhosis can develop due to mutation error in manganese 
transporter SLC30A10. This is a protective enzyme against manganese toxicity [11]. Over the 
last decade large numbers of cases of severe parkinsonism with dystonia have been recognized in 
Russia, Ukraine, the Baltic States and other parts of Eastern Europe following intravenous 
Ephedrone  abuse. This amphetamine like substance was synthesized by kitchen chemists by 
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mixing Coldact, a cold remedy containing pseudoephedrine  with Potassium permanganate for 
oxidation[4,12,13]. The clinical and neuroimaging picture closely resembled previous reports of 
severe chronic manganese poisoning [14-15].  Dopamine transporter imaging was normal[14]. 
The disease continued to progress despite drug cessation in some cases and dysarthria became 
the most disabling complaint for many patients[12]. 
 A quantitative acoustic analysis of Ephedrone induced dysarthria which was recently performed 
by Ruzs et al (16), revealed a distinct variant of mixed dysarthria with a combination of 
hyperkinetic and hypokinetic components representing the altered motor programming of 
dystonia and bradykinesia in Ephedrone-induced parkinsonism. We used perceptual speech 
analysis to evaluate further the pattern of speech disturbance in Ephedrone induced parkinsonism 
caused by chronic manganese toxicity and to compare it with the dysarthria seen in PD and 
Progressive Supranuclear Palsy (PSP)     
 
Materials and methods. 
 Fourteen  men (mean age 29.9), former Ephedrone addicts, who stopped injecting Ephedrone  
more than two years prior to speech assessment, were included in the speech study. All patients  
have been participating in the longitudinal UK-Ukraine study on Ephedrone induced dystonia 
with parkinsonism based at the Lviv Regional Clinical Hospital (Ukraine). A repeat neurological 
assessment, Mini-Mental examination (MMSE), video recording as well as repeat MR brain 
imaging were performed at the same time as speech assessment. Patient’s baseline clinical and 
imaging data, published previously, were used for analysis of the disease course. Five patients 
had DAT scans previously, which were all normal [15].Unified PD rating scales (UPDRS) on the 
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subjects was performed at the time of the speech evaluation by two experience neurologists (L.F. 
and M.S), with an expertise in Movement disorders [19]. Selective subscales of  UPDRS are 
presented in the table 1. In addition, Semi-quantitive scale was used for evaluation of  oro-motor 
function and dystonia of the limbs. Speech was graded according UPDRS, item 18: 0 = Normal; 
1 = Slight loss of expression, diction and/or volume; 2 = Monotone, slurred but understandable; 
moderately impaired; 3 = Marked impairment, difficult to understand; 4 = Unintelligible. 
Evaluation of speech included digital voice recording and consisted of diadochokinetic rate, 
maximum sustained phonation with sustaining the vowel /a/ in one breath; repetition   /pa/-/ta/-
/ka/ syllable as fast and as slow as they can for 30sec each; a one-minute monologue and 
repetition of the sentence “buy Bobby a puppy”. Speech recording was performed in a quiet 
room, using a head-mounted condenser microphone M-Audio MicroTrack 24/96 placed 
approximately 5 cm from the subject's mouth.  A detailed perceptual analysis of articulation, 
respiration, resonance, phonation, prosody, rate of speech, using a scale first recommended by 
Darley and colleagues (1975) scale, was then performed by both Ukranian and UK Speech 
therapists [18]. Rating of 6 speech subsystems from 0 (no function) to 7 (normal function)  with 
a total of 42.   
Written informed consent for the participation in research and video recording was provided 
by each patient.  
MR brain scans were performed (0.5 Tesla, GE medical Systems) using a T1 weighted sequence 
(TR, 500 milliseconds; TE, 11 milliseconds) in the coronal, sagittal and axial planes and a T2 
weighted sequence (TR, 4000 milliseconds; TE 80 milliseconds) in the axial plane;  The T1 
weighted images were inspected for the presence and severity T1 hyperintense signal change in 
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the basal ganglia and brain stem  nuclei in 14 anatomical structures. Evaluation of signal 
intensity was made by placing the region of interest (ROI) in areas with the highest intensity in 
the grey  matter defined by visual comparison with subcortical frontal white matter. This 
approach replicated the standard method of evaluation pallidal index [9].  Semi-quantitive 
analysis  with a 4 point rating scale and the signal intensity of normal frontal white matter (WM) 
as a reference was used.  
 MR data showed an abnormal T1 hyperintense signal in  11 of the 14 patients. Three patients 
who presented after 5 years of  exposure, had normal MRI studies. The MRI findings were 
evaluated by the neuroradiologist without knowledge of the clinical findings.  
 
Fifty four patients with Parkinson’s disease (PD) from the National Hospital for Neurology and 
Neurosurgery, who were assessed on- and off medication before and after one year of deep brain 
stimulation surgery, served as control groups. Mean age of the patients with PD was 58.8 years 
(±6.3), disease duration 12.5 years (±4.7), levodopa equivalent daily dose 1556 (± 671) and 
UPDRS-III off-medication 48.1 (±17.9) and on-medication 12.4 (± 7.8).  A smaller group of 5  
patients with probable PSP were also studied at the National Hospital. Their mean age was 69.9 
(±9.12) years, disease duration- 5(±3.3) years. By the time of speech assessment the patients had 
a prominent postural instability with the tendency to fall backwards, a marked  supranuclear  
gaze palsy, gate freezing (3), symmetrical akinetic-rigid syndrome unresponsive to LD, 
progressive disease course, no dementia, no hallucinations, cerebellar syndrome, no cortical 
sensory deficit. The speech pattern of both patients in the control groups was assessed using the 
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same perceptual scale (19) (Table 3). Statistics included two-tailed t-test or the Mann Whitney U 
test, as appropriate, for continuous variables, using STATISTICA version 6.0.   
Results.  
The first neurological symptoms developed after 6-12 months (8.5±3.2 months) of daily IV 
Ephedrone abuse including progressive dysarthria, slowness of movements, retropulsion, falls 
backwards, particularly on turning, apathy and abulia. One patient presented with manganese 
madness (code 3). The disease progression was fast within the first few weeks, then slowed 
down. Dysarthria was the initial symptom in 31% and continued to deteriorate after 6 months in 
most cases. Dystonia and tremor appeared later, in 6-12 months after the cessation of Ephedrone. 
Progression of dysarthria, dystonia and postural instability continued for months and years after 
of the drug cessation. This was evident in cases with prolong disease duration for  5-7 years. An 
average UPDRS total score was 51.6±14.6 compared to previous 45.8± 13.7 two years ago.  
The core neurological features in each patient are showen in table 1. All patients on the 
neurological examination had hypomimia with a constant dystonic grin, resembling a natural 
joyful expression, slow and jerky tongue movements, primitive reflexed of oral automatism and 
a forced involuntary laughter. Two patients had a mild hypersalivation and one- a mild difficulty 
with swallowing.  Palatal movements were normal. Dysarthria was moderate to severe in eleven 
out of 14 patients according to UPDRS score, item 18. Only three patients had a mild speech 
impairment (table 1). Patients complained that their speech had become slurred, slow, laboured 
and often hard to initiate.  Many reported a tight feeling in their throat, like a “lump”, a loss of 
speech volume and an inability to raise their voice. Two patients were mute (code 1 and 3), 
which developed within two years after cessation of the drug. There was a complete loss of 
initiation, no speech volume, slow tongue movements and palilalia was identified during their 
occasional effortful production of single words (yes- no).  
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Almost all patients had evident rigidity of axial muscles, whereas limbs rigidity was mild and 
belonged to lead-pipe type. Falls backwards and a staggering gait with dystonic posturing of the 
limbs and trunk, resembling “cock gait” were observed. Asymmetrical dystonic posturing of the 
feet, striatal toes, hands dystonia of “dinner folk” and pseudoparalisis patterns were evident. 
Apraxia of eyelid opening was seen in 9 patient. Ten patients had micrographia. Five patients 
had an assymmetrical actional tremor in their limbs. Rest tremor was rare. Severe dysarthria 
(score 3-4 on UPDRS- 18) was associated with more severe fine finger slowness, 2.5±0.5 
(UPDRS, item 23), compared to 1.4±0.8 on mild-moderate dysarthria (p=0.02). An average 
MMSE was 29 (±1.2).  
Most patients (8) had parkinsonism with dystonia phenotype. An interview of motor and speech 
symptoms showed that all patients with dystonic voice patterns had dystonia in the limbs, trunk 
and face (tables 1). Three patients with hypokinetic speech, without signs of dystonia presented 
with predominant parkinsonism phenotype with little or none limb dystonia. This observation is 
in keeping with the report of Rusz et al (2014), who showed a significant relationship  between 
several acoustic speech dimensions and the motor ratings of bradykinesia and dystonia [16]. In 
particularly, the dystonia severity correlated with speech timing parameters. Thus, the speech 
pattern was largely corresponding to the motor phenotype of Ephedrone induced parkinsonism.  
 
Levodopa test was performed on baseline assessment with Madopar dispersible 50/200 mg and 
showed less than 30 % response. The following LD trial did not show improvement: three 
discontinued Madopar therapy at doses between 300 and 500 mg/day because of intolerable 
nausea, 2 stopped taking 650 mg/day Madopar after 2 months without clinical benefit, and a 
further 2 patients were able to tolerate 750 mg a day for 3 months but failed to derive benefit.  
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Perceptual analysis of Ephedronic dysarthria 
Detailed results from perceptual analysis on each patient presented in the table 2.  
Phonation: All but one patients had a markedly reduced speech volume. Seven had a whispering 
pattern, including two patients with a complete aphonia. One patient had normal volume but with 
a continuous monotone voice and a complete inability to change pitch and loudness (monoloud) 
Five patients also had a strained-strangled dystonic voice quality. 
Prosody: Speech was monotonous in all patients, with lack of intonation and emphasis. Five 
patients had so restricted speech prosody that could be classified as robotic.  
Articulation: The main articulatory feature affected was the range of movement with minimum 
amount of lip and jaw movement (frozen upper lip). On non-speech oral mechanism examination 
there was also evidence of tongue rigidity and jerky movements (table 1).  The sounds were 
prolonged and with equal stress.  Palilalia was present in eight patients.  
Respiration:  Six cases had difficulty completing long sentences. Eight patients showed some 
difficulty with reduced breath support. Such difficulties could contribute to reduced physiologic 
support for speech and some of the overall phonatory and prosodic abnormalities  
Nasality: There was no perceptually prominent nasality.   
Rate: Rate was variably affected, either slow (N=7) with prolonged vowels or fast, festinating 
speech. (N=6).  Delay in initiation was observed in six. 
Comparison with parkinsonian dysarthria   
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The comparison of the average perceptual speech scores of patients with Ephedrone induced 
parkinsonism and patients with PD off- and on- medication and PD patients post bilateral 
Subthalamic nucleus– deep brain simulation (STN-DBS) are shown in table 2. Despite the fact 
that Ephedronic dysarthria can be broadly classified as hypokinetic, its severity is significantly 
greater than the dysarthria of patients with PD-medical group in all aspects of perceptual analysis 
with the exception of  phonation (table 3). The main areas of difference are prosodic impairment 
and articulation. The degree of monotonicity in Ephedronic dysarthria was much greater and the 
quality of voice was more robotic, due to the severe lack of stress and the continuous voicing. 
Articulation was also differently affected: in PD there was a lack of precision possibly due to 
spirantisation (i.e. articulatory undershooting, the replacement of stop with a fricative), whereas 
in Ephedronic dysarthria the main problem was that of reduced range of movements for lip and 
tongue muscles.  As can be seen from the table 3, the disturbance of articulation, respiration, 
phonation and prosody in Ephedronic dysarthria resemble in pattern and severity of the 
dysarthria  in cases of Parkinson’s disease after bilateral STN-DBS, with the exception of  
nasality [19]. 
Comparison with PSP dysarthria 
Speech in PSP patients was different from PD cases and characterized by monopitch with 
hoarseness, hypernasality, imprecise articulation and a slow rate. In comparison with the 
Ephedronic patients, the PSP group exhibited worse respiratory control for speech, a hoarse 
weak voice, imprecise articulation, and slower rate of speech and occasional hypernasality. 
Characteristics, more often presented in Ephedronic dysarthria, rather than PSP, include strained-
tight voice, monotone-monoloud speech, and variable speech rate. Similarities include the 
 11 
 
hypokinetic components, occasional presence of palilalia and the possibility of mutism. Both 
patient groups have shown difficulty with raising vocal volume on command and thus in making 
gains through behavioural therapy. These distinctions suggest that there is a different 
pathophysiology of speech in PSP than in PD patients.  
MR  brain image in  Ephedrone induced parkinsonism -dystonia.   
MRI findings are presented in Table 4. Patients with abnormal MRI all had symmetrical T1 
hyperintense signal in the Globus Pallidus (GP), the most severe in its medial part with an 
average score of 2.36, followed by the lateral pallidum (average score:1.82). Other frequently 
involved structures were the subthalamic nucleus and substantia nigra reticulate (SNr), showing 
hyperintensity in 6 and 7 patients, respectively. (fig. 1) The putamen showed lateral 
hyperintensity in seven patients. Involvement of posterior fossa structures was seen in less than 
half patients. The MRI studies performed closer to the time of drug exposure, showed more 
intense and more widespread T1 hyperintense signal changes. In the patients with severe 
neurological deficit MR signal change in the pallidum was still visible 3-5 years after the last 
exposure to ephedrone. MRI studies performed after 5 years of drug cessation were reported as 
essentially normal. (fig.2) The reversibitly of  MR signal change has previously also been 
documented in patients with liver failure after liver transplantation [9].   
Discussion 
Rodier (1955) first reported on severe speech disorder in chronic manganism: ”Neurological 
symptoms usually began with monotonous slow slurred speech with acquired stuttering, and 
muteness eventually ensues”[20]. Clinical and radiological features of Ephedrone induced 
parkinsonism are closely resemble previously described cases of severe manganism in miners. 
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This allowed us to observe and study more closely the pattern of speech. Levin (2005) described 
speech in Ephedronic encephalopathy as slow, hoarse, quiet, effortful and difficult to initiate. 
Three out of his 21 patients became mute and 14% had ataxic component of speech [21]. We 
performed a comparison of Ephedronic dysarthria with hypokinetic dysarthria in PD and PSP  
using  perceptual analysis (Darley 1975). Dysarthria in ex-Ephedrone users was an initial 
symptom in a third cases. Ephedronic speech was hypokinetic and monotonous, with 
inappropriately slow or accelerated speech rate. But they were unable to change pitch and 
loudness. 50% had whispering dysarthria.  Another distinguishing feature was a profound lack of 
prosody and lip articulation. Mutism is not a feature in PD, but was seen in Ephedrone induced 
disarthria (14%). Frequent palilalia (57%) and difficulties in initiation speech (43%) point 
towards the pallidal damage. By contrast to PD patients, over 74% ex -Ephedrone addict cases 
had a dystonic component resulted in prolonged and strained hypokinetic speech.  
Dysarthria of mixed type is typical for Parkinson plus syndromes. In PSP hypokinetic, spastic 
and ataxic types are consistently identified in various combinations, depending on the loci of the 
neuropathologic changes.  Slurred delayed speech with raspy or hoarse voice with a spastic 
component is often reported [22]. Dysarthria in our patients with PSP was associated with 
monopitch, hoarseness, nasal emission, hypernasality, imprecise articulation, slow rate, and a 
prominent mixed hypokinetic with spastic features. Similarly to PSP, Patients with Ephedrone 
induced parkinsonism were unable to increase the voice volume. However, in contrast to PSP,    
nasality was not a feature and there were whispering but otherwise intelligible consonants.  Also, 
swallowing was preserved even in most severe dysarthria cases by contrast to PSP. The absence 
of ataxic and nasal components distinguished Ephedrone dysarthia from the speech in MSA [23]  
Ephedrone induced dysarthria has perceptual similarity  with post STN-DBS speech in PD 
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patients. Astrom et al (2010) investigated the spread of the electrical current in post bilateral 
STN-DBS patients and found that patients with bilaterally medially placed electrodes (in the 
pallidothalamic tract) had more severely affected speech [24].  
Results of MRI scans which was done soon after Ephedrone exposure, showed T1 hyperintense 
signal change suggestive of bilateral striatal accumulation of manganese, predominantly in 
medial part of GP and to less degree in lateral putamen, SN reticulate and STN, similarly to 
imaging in chronic manganese poisoning [25]. Degeneration of nerve cells in pallidum, 
especially in the medial segment with a prominent demyelination and moderate  astrocytic 
proliferation has been reported in chronic manganism. [26] An exclusive role of GP in control of 
initiation of gait and speech was illustrated by Feve et al (1993), who presented four cases with 
pure circumscribed bilateral lesions of the Globus pallidum  after  a  hypoxic-ischemic event 
[27]. The clinical picture consisted of speech initiating difficulties with hypophonia and 
pallilalia-mutism and  a marked axial motor impairment but minimal distal rigidity, profound 
loss of postural reflexes, akinesia and gait freezing.   
 
The voice loudness and speech initiation was closely associated with involuntary laughter and 
abulia in Ephedrone induced parkinsonism. This was first reported by Levin (2005) who also 
noted a beneficial effect of SSRI on dysarthria [21] This observation is supported by the 
experimental data on vocalization in mammals, which found that the readiness of vocal 
expression is controlled by the limbic vocal pathway from anterior Cingulate cortex to phonatory 
motoneurons [29]. Akinetic rigid mutism due to bilateral lesions of the globus pallidus interna 
with ventral extension, disrupting the anterior cingulate frontal-subcortical circuit, has been  
reported [28].Functional neuroimaging would help to clarify the altered basal ganglia circuits, 
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responsible for manganese induced dysarthria . Hypophonic component of dysarthria showed 
some improvement with systematic speech therapy. Dystonic component remained unchanged or 
even worsened in our cases, similarly to the results from speech therapy in patients post bilateral 
STN-DBS[30]. Ephedronic dysarthria remains a debilitating syndrome requiring further 
investigation for its nature and symptoms management.  
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Table 1: Motor speech  control in Ephedrone induced Parkinsonism.   
 Patient 
number 1 2 3 4 5 6 7 8 9 10 11 12    13 14 
Speech  
UPDRS-18 4 4 4 4 3 2 2 2 1 1 2 3 1 2 
Signs 
duration, yrs 
      
5.5 
             
 4  2.5  
             
5 
         
 4 
     
 5.3     
        
4.5 
      
 2.5    
            
  7 2 2 
          
3.5 4.5 
            
 7 
Dystonic smile  +  + 
        
+ 
        
+ 
 
+++ 
            
 + 
        
+ 
         
+   + 
         
+ 
         
+ 
 
++  +  + 
Frozen upper 
lip +++ +++ 
    
+++ 
    
+++ 
   
+++ 
       
++ 
      
++ 
    
+++  ++ 
     
++ 
       
++ ++  + 
 + 
+ 
Tongue 
movement +++ 
    
+++ 
    
+++ 
    
+++ 
    
+++ 
       
++ 
        
+ 
    
+++  + 
        
0 
        
+ ++  +  + 
micrography +++  +  0 
       
+ 
       
+ 
        
+ 
        
0 
         
0  + 
       
0 
    
+++ + + 
 
++ 
Limb 
dystonia* 0  + 
       
++  ++ ++  
        
0 
      
++ 
       
+   + 
       
++        0 0 +  + 
apraxia eyelid 
opening   
             
+ 
      
+ 
        
+ 
        
+ 
          
+++ 
        
0 
       
0 
       
+   + 
        
+        0 0  +  0 
Tremor at rest  0 
       
0 
       
+ 
       
+ 
       
+ 
        
0 
       
+ 
       
0   0 
        
0        0 0  +  + 
Pull test 
UPDRS 30 2 3 3  3 3  2  3  3  2 2  2 2 1  1 
Axial rigidity 
UPDRS 22  3 3  3 2 2 1 2 1 1 2 3 2  1 2 
Finger tap 
UPDRS 23 3 3 3 3 3 2 1 3 1 2 2 1 1 2 
Grade of symptoms: + mild; ++ moderate; +++ severe presentation; 0-  absent. 
UPRDS subscales original version is used. *this score reflects the most affected limb. 
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Table 2. Speech perceptual analysis of Ephedrone induced dysarthria. 
      Patient’ code 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
     Darley score:      
        total 23 21 15 22 25 25 28 31 34 32 32 29 38 31 
    -  Articulation 4 3 3 4 4 4 5 5 6 5 5 5 7 4 
     -   Respiration 5 7 4 5 4 5 6 6 7 6 7 5 7 7 
           -   Nasality 7 7 5 7 5 5 6 7 7 7 7 7 7 7 
        -   Phonation 1 2 1 1 5 4 5 5 6 6 5 6 6 4 
           -   Prosody 2 1 1 1 4 4 3 4 4 4 4 3 4 4 
          -  Rate 4 1 1 4 3 3 3 4 4 4 4 3 7 5 
         Weak voice  +  + +  +  +  + +  +  0  +  + 0  0  + 
          Monotone  +  +  +  + +  +  +  +  +  +  +  + +  + 
        Monolaud  +  +  +  +  +  +  + +  +  +  +  +  +  + 
     Rate Slow/fast  fast slow slow slow slow  fast 
 
slow         fast fast       
 
slow         fast slow  0 
 
fast 
       Initial delay  +   +  +  + +   0  0  0  0 0  0  0  +  0 
           Palilalia  +  + + +  0  0  0   0 +  + 0 +  0 + 
  Voicing pattern 
      -hypokinetic     +  +   +  +  +  +  + +  +  +  +        +  + 
     Tight/dystonic  +  +   +  + +  +  + +  +  +          +               
- Robotic  + + + +   +     +   
      -  Contineous mute + mute  +   +     +   
      - Whispering  +  +  +  +    +         +     + 
Darley (1975) scale (18) rating from 0 (no function) to 7 (normal function), 42 total.  
Symptoms present: +; 0-  absent. 
 
 
 
 
 
 
 
 
 19 
 
 
Table 3 Comparison of dysarthria between Ephedronic Parkinsonism (N=14) and Parkinson’s Disease (N=54) 
Darley Ephedronic PD "off" P 1-2 PD "On" P 1-3 PD post P  1-4  
scale    
M±SD parkinsonism treatment 
 
treatment    DBS   
groups         (1)   (2) 
 
 (3) 
 
 (4) 
 Articulation 4.57±1.09 5.9 ±0.8 0,0002 5.6±1.3 0,03 4.4±1.9 0,3 
Respiration 5.78±1.12 5.0±1.0 0,05 4.9±1.1 0,04 4.4±1.9 0,02 
Resonance 6.5±0.85 5.6±1.0 0,01 5.6±0.8 0,007 4.9±1.6 0,001 
Phonation 4.07±1.98 4.8±1.0 0,1 5.1±1.0 0,09 4.4±1.5 0,3 
Prosody 3.07±1.27 4.9±1.5 0,001 5.3±1.4 0,0001 4.1±1.8 0,09 
Rate 
control 3.57±1.50 6.0±0.9 0,001 5.8±1.3 0,0001 5.2±1.6 0,01 
Total score 27.6±6.1 32.4±4.6 0,02 32.5±5.2 0,02 27.3±8.8 0,3 
Scale by Darley et al (1975) (18) with rating from 0 (no function) to 7 (normal function), total out of 42. The 
table show the comparison of the average perceptual scores in patients with ephedronic parkinsonism (1) with PD 
patients, who were assessed off- medication (2), on- medication (3) and then after Bilateral STN-DBS (4).It showed 
a significant difference (P-value) in all parameters between 1-2 groups, wherease there was no difference in 4 
parameters in 1-4 comparison.    
 
Table 3. MRI findings in Ephedronic Encephalopathy 
patient’s code  1 3 4 5 7 8 9 10 11 12 13  
years disease to MRI 2.5 0.4 5 1 3 0.4 1 0.4 0.5 0.5 1.5  
n.caudate head 0 0 0 0 0 0 0 0 1 0 0  
 n.caudate rim 0 0 0 0 0 0 0 0 2 0 0  
 n.caudate body 0 0 0 0 0 2 0 0 1 0 0  
gl.pallid med 3 3 2 3 1 2 3 2 3 3 1  
gl.pallidum lat 3 2 1 2 1 1 2 2 3 2 1  
Putamen 0 1 0 1 1 2 0 1 2 1 0  
Putamen lat rim 1 2 0 2 0 0 0 2 3 0 0  
Thalamus 0 0 0 0 0 0 0 0 0 0 0  
STN 2 2 0 0 0 2 0 2 2 2 0  
SN 1 1 0 2 0 2 0 1 2 2 0  
sup cerebellar ped 0 1 0 2 0 2 0 0 2 0 0  
n.dentatus Left 0 0 0 1 0 0 0 2 0 0 0  
n.dentatus R 0 0 0 0 0 0 0 1 0 0 0  
Pons rostral 0 0 0 2 0 2 0 2 2 0 0  
The table lists the visual score of pathological signal increase on T1 weighted images in 14 anatomical structures. 
Grading for gray matter structures: 0, normal appearance; 1- isointense to WM; 2- hyperintense to WM; 3- markedly 
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hyperintense to WM. Grading for white matter: 0- normal; 1- hyperintense to WM; 2- markedly hyperintense to 
WM. 
 
Fig. 1 MR brain image in Ephedrone induced parkinsonism.    
Fig. 1  Two Non-enhanced  coronal T1 weighted MR images showing bilateral markedly hyperintense signal 
in the globus pallidus, most severe in its medial part and, to a lesser degree in the substantia nigra reticulate, 
subthalamic nuclei, putamen  and caudate nucleus.  The Picture below: Normal repeat MR brain image in 
Ephedrone induced parkinsonism after 5 years without exposure.    
Video Legend  “Ephedronic dysarthria”  
Segment  1 Patient  12.  26 y.o.,  with Ephedrone induced parkinsonism . 5.5 years of drug cessation . Continueous , 
tight robotic speech. No  significant hypokinetic features.     
Segment 2  
 Patient  7. 33 y.o.,  severe Ephedrone induced parkinsonism with dystonia. 8.5 years of drug cessation . 
Hypokinetic,  continueous , tight robotic speech.  
Segment 3 
  Patient  2. 33 y.o., severe Ephedrone induced parkinsonism with dystonia.   Hypokinetic,  whispering, continueous,  
tight robotic speech.  
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